NU Lin

1.7k total citations
41 papers, 230 citations indexed

About

NU Lin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, NU Lin has authored 41 papers receiving a total of 230 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in NU Lin's work include Cancer Treatment and Pharmacology (14 papers), Advanced Breast Cancer Therapies (12 papers) and HER2/EGFR in Cancer Research (12 papers). NU Lin is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Advanced Breast Cancer Therapies (12 papers) and HER2/EGFR in Cancer Research (12 papers). NU Lin collaborates with scholars based in United States, Italy and Canada. NU Lin's co-authors include Sandro Santagata, Luke Whitesell, Eric P. Winer, Yi Zhou, Xin Lian, Joyce C. Niland, Ann Vanderplas, Stephen B. Edge, Yao Liang Wong and Douglas W. Blayney and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

NU Lin

35 papers receiving 221 citations

Peers

NU Lin

ONCOL

PRM

RNMI

Dionysis Papadatos-Pastos United Kingdom

Mathias Tesson United Kingdom

Eric Haines United States

Judit Matito Spain

Johanna Sjöström Finland

Franziska Niehr Germany

D. Solit United States

Tong Luo United States

Andy Futreal United States

António Pêgo Portugal

Dionysis Papadatos-Pastos United Kingdom

NU Lin

99 ×0.7

ONCOL

136 ×1.6

73 ×1.1

PRM

56 ×0.9

36 ×0.9

RNMI

Citations per year, relative to NU Lin NU Lin (= 1×) peers Dionysis Papadatos-Pastos

Countries citing papers authored by NU Lin

Since Specialization

Citations

This map shows the geographic impact of NU Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by NU Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites NU Lin more than expected).

Fields of papers citing papers by NU Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by NU Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by NU Lin. The network helps show where NU Lin may publish in the future.

Co-authorship network of co-authors of NU Lin

This figure shows the co-authorship network connecting the top 25 collaborators of NU Lin. A scholar is included among the top collaborators of NU Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with NU Lin. NU Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Yusheng, Zheng Chen, NU Lin, Yu Liu, & Xuefeng Jiang. (2025). Evaluating the psychosocial effects of cancer on sleep quality and mental health in elderly populations. BMC Psychiatry. 25(1). 933–933.

Lin, NU, et al.. (2025). Is the Increase in Tumour Markers and Hashimoto’s Thyroiditis an Incidental Event During Dupilumab Treatment? A Case Report. Acta Dermato Venereologica. 105. adv41250–adv41250.

Corti, Chiara, Xun Chu, Pedro Exman, et al.. (2025). Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study. ESMO Open. 10(8). 105521–105521.

Tarantino, Paolo, Qingchun Jin, Rinath Jeselsohn, et al.. (2022). 1MO Prognostic and biologic significance of HER2-low expression in early breast cancer. Annals of Oncology. 33. S124–S124. 5 indexed citations

Bachelot, Thomas, NU Lin, Sara A. Hurvitz, et al.. (2020). 293P Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases. Annals of Oncology. 31. S359–S360. 9 indexed citations

Exman, Pedro, et al.. (2019). Abstract P1-17-02: Outcomes and safety of paclitaxel and granulocyte-colony stimulating factor (GCSF) in breast cancer in pregnancy (BCP) - A multi-institutional retrospective analysis. Cancer Research. 79(4_Supplement). P1–17. 2 indexed citations

Vaz-Luís, Inês, Antonio Di Meglio, Mayssam El-Mouhebb, et al.. (2018). Breast cancer (BC) related fatigue: A longitudinal investigation of its prevalence, domains and correlates. Annals of Oncology. 29. viii605–viii605. 3 indexed citations

Winer, EP, et al.. (2018). Abstract P4-10-04: EMBRACE (Ending metastatic breast cancer for everyone): A comprehensive approach to improve the care of patients with metastatic breast cancer. Cancer Research. 78(4_Supplement). P4–10. 1 indexed citations

Lin, NU, et al.. (2016). Abstract OT3-01-04: An open-label, single-arm, phase II study of pertuzumab with high-dose trastuzumab for the treatment of central nervous system progression post-radiotherapy in patients with HER2-positive metastatic breast cancer (PATRICIA). Cancer Research. 76(4_Supplement). OT3–1. 1 indexed citations

10.

Lin, NU, et al.. (2015). Expression of microRNA-106b and its clinical significance in cutaneous melanoma. Genetics and Molecular Research. 14(4). 16379–16385. 16 indexed citations

11.

Reardon, David A., Lakshmi Nayak, Lisa M. DeAngelis, et al.. (2014). P15.13 * THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE: A TOOL TO ASSESS NEUROLOGIC FUNCTION FOR INTEGRATION IN THE RADIOLOGIC ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA. Neuro-Oncology. 16(suppl 2). ii76–ii76. 5 indexed citations

12.

Whitesell, Luke, Sandro Santagata, & NU Lin. (2012). Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution. Current Molecular Medicine. 12(9). 1108–1124. 53 indexed citations

13.

Lin, NU, et al.. (2012). Abstract P6-08-03: Informational needs and psychosocial assessment of patients in their first year after metastatic breast cancer diagnosis. Cancer Research. 72(24_Supplement). P6–8. 1 indexed citations

14.

Krop, IE, Julie Najita, Ingrid A. Mayer, et al.. (2011). The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003.. Journal of Clinical Oncology. 29(15_suppl). 528–528. 3 indexed citations

15.

Anders, Carey K., Rachita Nanda, Kim T. Blackwell, et al.. (2011). TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM).. Journal of Clinical Oncology. 29(15_suppl). TPS127–TPS127. 3 indexed citations

16.

Lin, NU, Ingrid A. Mayer, Julie Najita, et al.. (2011). TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). 527–527. 8 indexed citations

17.

Lin, NU, H. S. Rugo, Rita Nanda, et al.. (2011). TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer.. Journal of Clinical Oncology. 29(15_suppl). TPS128–TPS128. 2 indexed citations

18.

Bardia, Aditya, Lori J. Sokoll, J. N. Ingle, et al.. (2010). Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study.. Journal of Clinical Oncology. 28(15_suppl). 1001–1001. 2 indexed citations

19.

Lin, NU, Ann Vanderplas, Melissa E. Hughes, et al.. (2009). Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). Journal of Clinical Oncology. 27(15_suppl). 543–543. 29 indexed citations

20.

Lin, NU, Gloria Broadwater, L. G. Dressler, et al.. (2004). The predictive value of HER2 and p53 on outcomes after paclitaxel chemotherapy for metastatic breast cancer: Results from CALGB 9342. Journal of Clinical Oncology. 22(14_suppl). 9562–9562. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact